1. Scrip

OncoSec Pushes IL-12 Approach Forward In PD-1 Melanoma Failures

 
• By Emily Hayes

Company plans to pursue accelerated approval based on a single-arm registrational study of PD-1 failures, after reporting positive results from a Phase II study at the ASCO-SITC meeting.

OncoSec antibody
• Source: OncoSec

OncoSec Medical Inc. says that its approach for delivering the anticancer protein interleukin-12 directly to tumors is likely to work in combination with PD-1 inhibition in melanoma patients who failed a PD-1 inhibitor, based on results from a small, single-arm Phase II study. It is now planning a registrational trial in PD-1 failures.

OncoSec's proprietary ImmunoPulse platform delivers DNA-based therapeutics directly into tumors, eliciting a local but also a systemic approach, according to the company

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Clinical Trials

More from R&D

Azafaros Banks Over €130m To Advance Nizubaglustat Into Phase III

 
• By Kevin Grogan

The therapy has been developed for GM1 and GM2 gangliosidoses and Niemann-Pick disease type C.

Lilly Builds Obesity Momentum With New SURMOUNT Data Besting Novo Nordisk

 
• By Alaric DeArment

The presentation and publication of the Phase IIIb study showing greater efficacy for Zepbound over Wegovy come at a time when competition has been heating up between the two obesity medications.

Which Firms Are Most Exposed To Prasad’s Possible Accelerated Approvals Clampdown?

 
• By Andrew McConaghie

Vaccine and accelerated approvals are expected to face greater scrutiny under new CBER leader Vinay Prasad, but he has promised “no light switch change” to policy, giving some reassurance to companies whose share prices have been battered.